A review on dronedarone: Pharmacological, pharmacodynamic and pharmacokinetic profile

详细信息    查看全文

• 作者：Farah Iram¹ ; Sadaf Ali¹ ; Aftab Ahmad² ; Shah Alam Khan³ ; Asif Husain¹ ; ^{drasifhusain@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; ^{ahusain@jamiahamdard.ac.in" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Multaq ; Antiarrhythmic ; Atrial fibrillation ; Cardiac arrhythmia ; Sinus rhythm
• 刊名：Journal of Acute Disease
• 出版年：2016
• 出版时间：1 March 2016
• 年：2016
• 卷：5
• 期：2
• 页码：102-108
• 全文大小：362 K

文摘

Dronedarone, a benzofuran containing chemical compound, is a derivative of amiodarone which is classified as a Class III antiarrhythmic agent. It is prescribed to the cardiovascular patients who have paroxysmal or persistent atrial fibrillation to lower the chances of hospitalization. Amiodarone, sotalol, procainamide dofetilide, quinidine, ibutilide, flecainide, and propafenone are the other useful medicinal products used to treat atrial fibrillation or cardiac arrhythmia. Dronedarone was approved for clinical use in atrial fibrillation by the Food and Drug Administration in 2009. The generic name for dronedarone is Multaq (Sanofi Aventis). This article briefly highlights the important pharmacological, pharmacodynamic and pharmacokinetic properties of dronedarone.